Skip to main content
logo
Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $19.53M in the quarter ending June 30, 2025, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $85.39M, down -1.34% year-over-year. In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth.

Revenue (ttm)
$85.39M
Revenue Growth
-1.34%
P/S Ratio
4.54
Revenue / Employee
$821,010
Employees
104
Market Cap
391.22M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202487.69M2.87M3.38%
Dec 31, 202384.82M19.55M29.96%
Dec 31, 202265.27M30.37M87.03%
Dec 31, 202134.90M14.15M68.18%
Dec 31, 202020.75M--
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

YMAB News

More News